



June 20, 2016

Presiding Judge William Morse
Nesbett Courthouse
825 W 4th Ave, Rm 601
Anchorage, Alaska

Hand Delivered

Re: Administration Rule 37.7 Research Request

Dear Presiding Judge Morse:

This is a request under Administration Rule 37.7 for access to 30 consecutive court files where a Petition for Court Approval of Administration of Psychotropic Medication, under AS 47.30.839 was filed, starting on January 1, 2016, in order to conduct the research set forth in the attached Research Protocol: "Forced admission and forced treatment in psychiatry: are patients' rights being respected? (Research Protocol)." Also attached is the *Curriculum Vitae* of Peter C. Gøtzsche, MD, the principle investigator under the Research Protocol.

As the Research Protocol specifies, personal identification of the respondents is not necessary or desired:

It is not necessary to know the patients' names. To preserve anonymity, these can be redacted before we get access to the documents, or we could sign a legally binding confidentiality agreement. In any case, we will report the results in a way that does not allow identification of any of the patients.

I understand having court personnel redact the documents might be a burden, especially in the current budgetary climate, and I am willing to redact the documents prior to transmitting them to the researchers if that would help. Otherwise, the commitment of the researchers not to report the results in a way that allows identification of the Respondents should suffice.

As his *Curriculum Vitae* shows, the principle investigator, Dr. Gøtzsche, has quite impressive research credentials, being one of the founders of the Cochrane Collaboration, having had 70 papers published in the big five medical journals (British Medical Journal, Lancet, Journal of the American Medical Association, Annals of Internal Medicine, and the New England Journal of Medicine), being the author of four books, and having his scientific works cited over 15,000 times.

Presiding Judge William Morse


June 20, 2016

Page 2

Rule 37.7(a) provides that access to non-public court records, such as requested here, is allowable if the requestor's interest in disclosure outweighs the potential harm to the person whose interests are being protected, including consideration of (1) risk of injury to individuals, (2) individual privacy rights and interests, (3) proprietary business information, 4) the deliberative process, or 5) public safety.

Here, because identifying information will be protected there is no potential harm to the people whose interests are being protected and none of the other considerations listed for denying such a request exist. On the other side of the scale, the requestor's interest is quite compelling. The opportunity to have such an internationally recognized researcher analyze the extent to which petitions under AS 47.30.839 comply with the requirements set forth in *Myers*¹ and *Bigley*,² and compare them with Danish analogues will be extremely valuable.

Yours truly,

A handwritten signature in blue ink, appearing to read 'James B. Gottstein', with a long, sweeping flourish extending to the right.

James B. Gottstein, Esq.

cc: Peter C. Gøtzsche, MD
Steve Bookman (via e-mail)
Linda Beecher (via e-mail)

Enc. Forced admission and forced treatment in psychiatry: are patients' rights being respected? Research Protocol

Curriculum Vitae for Peter C. Gøtzsche-last updated in January 2016

¹ *Myers v. Alaska Psychiatric Institute*, 138 P.3d 238 (Alaska 2006).

² *Bigley v. Alaska Psychiatric Institute*, 208 P.3d 168 (Alaska 2009).

Forced admission and forced treatment in psychiatry:
are patients' rights being respected?

research protocol

Peter C Gøtzsche¹ and Anders Sørensen²

¹Professor, DrMedSci, MSc
Nordic Cochrane Centre
Copenhagen
Denmark
pcg@cochrane.dk

²Psychologist
Nordic Cochrane Centre
Copenhagen
Denmark
anders.ks90@gmail.com

17 June 2016

When patients resist forced treatment orders in psychiatry, the legal procedure usually is that the psychiatrists appeal the patients' decision to a local court. The court's ruling can be appealed to a higher court.

In *Myers v. Alaska Psychiatric Institute*,¹ the Alaska Supreme Court held, that in non-emergency cases under AS 47.30.839, a court may not permit a treatment facility to administer psychotropic drugs unless in addition to the statutory requirements, the court expressly finds by clear and convincing evidence the proposed treatment is in the patient's best interests and no less intrusive alternative is available.

In *Bigley v. Alaska Psychiatric Institute*, the Alaska Supreme Court held that a less intrusive alternative is available if it is feasible and, if a less intrusive alternative is feasible, the hospital must provide it or release the person.² *Bigley* also held that when seeking the involuntary administration of psychotropic medication under AS 47.30.839 the petition must provide a plain, concise and definite written statement of the facts underlying the petition, including the nature of and reasons for the proposed treatment and information about the patient's symptoms and diagnosis; the medication to be used; the method of administration; the likely dosage; possible side effects, risks and expected benefits; and the risks and benefits of alternative treatments and nontreatment.³

On June 1, 2016, Peter Gøtzsche testified in an AS 47.30.839 proceeding held in Anchorage, Alaska, and in connection with that reviewed four AS 47.30.839 petitions. All four petitions were strikingly similar and failed to provide the information required in the *Bigley* case.

In Denmark and elsewhere, there are similar problems as in Alaska in relation to court cases of forced drugging of psychiatric patients. This is clear from the many emails we have received from patients and their relatives from all over the world; from contacts we have had to lawyers for the defence; and from a Norwegian superior court case where Peter Gøtzsche provided expert testimony in 2015.

We therefore wish to investigate more formally, in two cohorts of cases, to which extent and how the legal predicates for the involuntary administration of psychotropic medication orders are lacking, comparing and contrasting Anchorage, Alaska and Copenhagen, Denmark.

Methods

We will collect the court files for 30 consecutive AS 47.30.839 petitions, from Anchorage and 30 comparable cases from Copenhagen, with 1 January 2015 as the starting date. Based on the written material available to us, we will evaluate if:

¹ 138 P.3d 238, 254 (Alaska 2006).

² 208 P.3d 168, 182 (Alaska 2009).

³ 208 P.3d at 188.

1. The petitions comply with the requirements of *Bigley* in Alaska and Danish requirements in Denmark.
2. Information is provided that documents that the patient cannot provide informed consent.
3. Information about the psychiatric drugs the patient takes or will be forced to take is accurate.
4. A less intrusive alternative is available.
5. The combination of drugs the patient takes is safe.
6. The arguments for using force are reasonable and documented.
7. The patients' rights have been respected.
8. There are striking similarities from case to case considering that patients are different.

Furthermore, the judge's ruling will be noted.

Data analysis

This is a qualitative study and the statistics being used will mainly be descriptive. We will test whether the legal predicates for the involuntary administration of psychotropic medication orders have been met with a chi-square test and compare the results from Anchorage with those from Copenhagen, also with a chi-square test.

Ethical considerations

It is not necessary to know the patients' names. To preserve anonymity, these can be redacted before we get access to the documents, or we could sign a legally binding confidentiality agreement. In any case, we will report the results in a way that does not allow identification of any of the patients.

Publication

We will publish our results in a peer reviewed journal taking relevant ethical, legal and scientific considerations into account, as described in the literature and summarised on websites and in books.^{4 5 6}

⁴ Gottstein JB. Psychiatry: Force of Law. <http://psychrights.org/>.

⁵ Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015.

⁶ Breggin P. Brain-disabling treatments in psychiatry: drugs, electroshock and the psychopharmaceutical complex. New York: Springer; 2007

Curriculum vitae

for

Peter C. Gøtzsche

last updated in January 2016

Contents

Personal data	3
Education.....	3
Appointments	3
Pregraduate.....	3
Postgraduate, previous	3
Postgraduate, current	4
Funding support.....	4
Awards and other academic honours	5
Publications	5
DrMedSci thesis	5
Textbooks	5
Travel book	6
Journal articles, book chapters and similar	6
Correspondence, book reviews and similar.....	20
Secondary publications in Danish	30
Teaching	30
Pregraduate courses.....	30
Postgraduate courses	31
Lectures	34
Research mentorships.....	44
Scientific assignments	45
General	45
Editorial work.....	46
Chairman at congresses and meetings.....	47
Advisory Board member at international congresses.....	48
Expert witness in court cases	48
Management experience.....	48

Personal data

Name: Peter Christian Gøtzsche
 Address: Kløvervang 39, 2970 Hørsholm
 Telephone: 45 86 88 66
 Date of birth: 26 November 1949
 Family relation: Married, 2 children
 Citizenship: Danish

Title: Director, Chief Physician
 Academic titles: MD, DrMedSci, MSc (biology and chemistry), fil. mag.
 Address: The Nordic Cochrane Centre, Rigshospitalet, Dept. 7811, DK-2100 Copenhagen
 Work phone: 35 45 70 04
 Fax: 35 45 70 07
 Email: pcg@cochrane.dk

Education

1968 Student exam, Næstved Gymnasium. Marks: 9.0.
 1970 First part of biology, University of Copenhagen. Marks: ug-.
 1970-73 Studies at the universities of Uppsala and Lund.
 1973 Fil. mag. in biology, University of Lund.
 1974 MSc (cand. scient.), University of Copenhagen, zoology and chemistry.
 Special subject in entomology. Marks only in this: 10.
 1984 MD, University of Copenhagen. Marks: 10.0.
 1990 Thesis, University of Copenhagen.
 1995 Specialist in internal medicine.

Appointments

Pregraduate

01.04.75 - 31.03.77 Drug representative and product manager, Astra Group A/S.
 01.04.77 - 31.08.83 Chief of medical department, Astra-Syntex A/S.

Postgraduate, previous

		months
01.06.84 - 30.09.84	Registrar, Bispebjerg Hospital, Med Dept C	4
01.10.84 - 31.12.85	Registrar, Herlev Hospital, Surgical Dept	12
01.06.85 - 31.08.85	Registrar, Herlev Hospital, Med Dept F	3
01.01.86 - 31.08.86	Registrar, Rigshospitalet, Dept of Infect Dis	8
01.09.86 - 30.09.87	Registrar, Hvidovre Hospital, Dept of Hepatology	13
01.09.87 - 31.05.95	Chief, Nordic coordination office for AIDS trials, Rigshospitalet	93
01.09.88 - 31.01.90	Junior Lecturer, Theory of Medicine, University of Copenhagen	17
01.02.89 - 28.02.90	Registrar, Herlev Hospital, Med Dept C	11
01.03.90 - 28.02.91	Registrar, Rigshospitalet, Med Dept A	12
01.03.91 - 31.08.91	Registrar, Rigshospitalet, Med Dept L	6
01.09.91 - 29.02.92	Registrar, Rigshospitalet, Dept of Infect Dis	6
01.03.92 - 30.06.93	Senior registrar, Hvidovre Hospital, Dept of Rheumatology	16
01.09.92 - 30.06.93	Lecturer, internal medicine, Hvidovre Hospital	10
01.07.93 - 31.08.95	Senior registrar, Rigshospitalet, Dept of Infect Dis	12
01.10.93 - 31.05.97	Senior House Medical Officer, Rigshospitalet	45
01.03.92 - 31.12.98	Editor, Bibliotek for Læger	82
01.02.90 - 31.03.10	Lecturer, Theory of Medicine, University of Copenhagen	242

Postgraduate, current

01.10.93 - Director, The Nordic Cochrane Centre
 01.06.97 - Chief physician, Rigshospitalet
 01.04.10 - Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

1987 Danish Medical Research Council
 1988 Danish Medical Research Council
 1989 Danish Medical Research Council
 1990 Danish Medical Research Council
 1990 Danish Arthritis Foundation
 1992 Medical Society in Copenhagen
 1992 Fund for progress in Medical Science
 1992 Danish Arthritis Foundation
 1993 Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
 1993 Ministry of Health
 1994 Rigshospitalet
 1994 European Union, BIOMED I
 1995 European Union, BIOMED II
 1995 Nordic Council of Ministers
 1995 Rigshospitalet
 1995 Copenhagen Hospital Foundation
 1996 Danish Medical Research Council
 1996 Nordic Council of Ministers
 1996 Apothecary Foundation
 1997 Nordic Council of Ministers
 1997 Sygekassernes Helsefond
 1997 Research Fund, Leo Pharmaceuticals
 1998 European Union, BIOMED 2
 1998 Nordic Council of Ministers
 1998 Danish Medical Research Council
 1999 Nordic Council of Ministers
 1999 State Institute for Medical Health Technology Assessment
 2000 Nordic Council of Ministers
 2000 Ministry of Health
 2001 Nordic Council of Ministers
 2002 Nordic Council of Ministers
 2003 Danish Medical Research Council
 2003 Danish Ministry of Health
 2003 Rigshospitalet
 2003 Nordic Council of Ministers
 2004 Nordic Council of Ministers
 2005 Nordic Council of Ministers
 2006 Nordic Council of Ministers
 2006 IMK Charitable Fund
 2007 Danish Medical Research Council
 2007 The Cancer Foundation
 2008 Nordic Council of Ministers
 2008 Sygekassernes Helsefond
 2008 Rigshospitalet
 2008 Danish Medical Research Council
 2009 Rigshospitalet
 2009 Capital Region of Denmark
 2009 Agnes and Poul Friis' Foundation
 2010 Augustinus Foundation
 2010 Oticon Foundation

2010	Rigshospitalet
2010	Lundbeck Foundation
2010	Kontorchef Gerhard Brønsted's Travel Grant
2010	Tryg Foundation
2010	University of Copenhagen
2010	Sygekassernes Helsefond
2010	Julie von Müllen's Foundation
2010	The Free Research Councils
2011	The Cochrane Collaboration
2011	Rigshospitalet
2012	Rigshospitalet
2012	Tryg Foundation
2012	Sygekassernes Helsefond
2012	The Cochrane Collaboration
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2015	University of Copenhagen, PhD stipend
2014	Laura and John Arnold Foundation, Houston, Texas, , PhD stipend

In addition, we have received support from The Cochrane Collaboration 2003-2015 that comes from royalties through sales of licences to The Cochrane Library (The Cochrane Collaboration is registered as a charity).

Awards and other academic honours

1992	Farmer from Stenløse, Peder Laurids Pedersen's donation.
1997	Award of the year from the foundation "A good start in life".
1999	Henrik R. Wulff's prize from Danish Society for Theory in Medicine
2001	Skrabaneck Foundation Prize, Trinity College, Dublin.
2001	Niels A. Lassen's prize.
2003	Queen Ingrid's Lecture, Åbenrå Hospital.
2004	Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting.
2006	Top-ten peer reviewer for British Medical Journal for the year 2006.
2007	Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. <i>BMJ</i> 2006;332:538-41).
2009	Michael Berger award, Düsseldorf.
2012	Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388).
2014	Winner of the Annual LAP Award (psychiatry award), Denmark.
2014	Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for Deadly Medicines and Organised Crime: How big pharma has corrupted health care.
2014	Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex."
2015	Honourable Award, Consul General Ernst Carlsen's Foundation.
2015	Book of the Year, US Tributaries Radio, for Deadly Psychiatry and Organised Denial.

Publications

DrMedSci thesis

Bias in double-blind trials. *Dan Med Bull* 1990;37:329-36. Review that refers to references 12 and 23-27. Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Textbooks

Wulff HR, Gøtzsche PC. *Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger*, 4. udgave. København: Munksgaard, 1997:1-278.

- Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific, 2000:1-221.
Translated into Swedish, Spanish and Polish.,
- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark, 2006:1-304.
- Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley, 2007:1-229.
- Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388.
- Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013.
Translated into many languages.
- Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumpet sundhedsvæsenet. København: People's Press, 2013.
- Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015.
Will be translated into many languages.
- Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People's Press; 2015.

Travel book

Gøtzsche PC. På safari i Kenya. København: Samlerens forlag, 1985:128 sider.

Journal articles, book chapters and similar

Total number of citations: more than 14,000; H-index: 51 (Web of Science).

1. Gøtzsche PC. Vandtæggers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. *Scand J Rheumatol* 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1983;145:3902-4.
4. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. *Pharmatherapeutica* 1984;3:535-41.
5. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. *Community Dent Oral Epidemiol* 1985;13:244-6.
6. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin's disease than to other tumours or to infection. *Scand J Haematol* 1985;35:325-8.
7. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. *Int J Oral Maxillofac Surg* 1986;15:389-94.
8. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. *Nord Med* 1986;101:24-5.
9. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholt EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. *Ugeskr Læger* 1986;148:1266-8.
10. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. *Ugeskr Læger* 1986;148:2417-20.
11. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? *Ration Drug Ther* 1986;20:1-7.
12. Gøtzsche PC. Reference bias in reports of drug trials. *BMJ* 1987;295:654-6.
13. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. *BMJ* 1988;296:820-2.
14. Ørnkov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. *Ugeskr Læger* 1988;150:897-900.
15. Gøtzsche PC, Hørting M. Condoms to prevent HIV transmission do not imply truly safe sex. *Scand J Infect Dis* 1988;20:233-4.

16. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. *Scand J Rheumatol* 1988;17:11-6.
17. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). *Ugeskr Læger* 1988;150:1765-6.
18. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. *Scand J Infect Dis* 1988;20:395-402.
19. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. *Ugeskr Læger* 1988;150:2250-2.
20. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i *Ugeskrift for Læger* gennem 25 år. Artikeltype og forsøgsdesign. *Ugeskr Læger* 1989;151:218-20.
21. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i *Ugeskrift for Læger* gennem 25 år. Analyse og tolkning af forsøgsresultater. *Ugeskr Læger* 1989;151:220-2.
22. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalalgia* 1989;9:29-32.
23. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. *Lancet* 1989;i:88-91.
24. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 1989;10:31-56 (amendment:356).
25. Gøtzsche PC. Multiple publication in reports of drug trials. *Eur J Clin Pharmacol* 1989;36:429-32.
26. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. *Dan Med Bull* 1989;36:395-9.
27. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. *Dan Med Bull* 1989;36:493-5.
28. Gøtzsche PC. Medicinske studenters holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. *Ugeskr Læger* 1989;151:2719-21.
29. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. *Internat J Immunopharmacol* 1990;12:145-7.
30. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. *AIDS* 1990;4:233-8.
31. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. *Scand J Infect Dis* 1990;22:283-5.
32. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbagi I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. *AIDS* 1990;4:1037-8.
33. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbagi IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielski P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. *AIDS* 1990;4:1168-9.
34. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *J Clin Epidemiol* 1990;43:1313-8.
35. Hørding M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. *Biomed Pharmacother* 1990;44:475-8.
36. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. *AIDS* 1990;4:1111-6.
37. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsklen til det 21. århundrede. *Bibliotek for Læger* 1991;183:69-82.
38. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. *Scand J Clin Lab Invest* 1991;51:93-7.
39. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. *Scand J Infect Dis* 1991;23:509-10.
40. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. *Dan Med Bull* 1991;38:405-7.
41. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. *J Virol Methods* 1991;35:15-25.

42. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. *Dan Med Bull* 1991;38:476-8.
43. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. *BMJ* 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
44. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbelblindforsøg og forslag til forbedringer. *Månedsskr Prakt Lægegern* 1992;70:159-64.
45. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Jarner D, Friis J, eds. *Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoides*. København: Astra, 1992:18-30.
46. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. *J Clin Epidemiol* 1992;45:587-94.
47. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. *Antiviral Res* 1992;18:303-16.
48. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. *Scand J Infect Dis* 1992;24:563-5.
49. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. *Bibliotek for Læger* 1993;185:17-29.
50. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. *J Clin Epidemiol* 1993;46:319-21.
51. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. *BMJ* 1993;306:1093-6.
52. Gøtzsche PC. Zidovudine in HIV infection. *Ann Med* 1993;25:213-4.
53. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. *Int J Obes* 1993;17:323-7.
54. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. *Scand J Rheumatol* 1993;22:255-60.
55. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlingers effekter. *Nord Med* 1994;109:244-5.
56. *The Cochrane Collaboration Handbook*. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.
57. Gøtzsche PC. Meta-analyser og kvalitetssikring. *Journal* 1994;2:16-7.
58. Gøtzsche PC. Is there logic in the placebo? *Lancet* 1994;344:925-6.
59. Gøtzsche PC. Er placebobegrebet logisk? *Bibl Læger* 1995;187:71-8.
60. *Rigshospitalets Forskningspolitik*, 1994, 16 pp.
61. Gøtzsche PC. Supplement til *Rigshospitalets Forskningspolitik*, 1994, 40 pp.
62. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? *J Intern Med* 1994;236:599-601.
63. *The Standards of Reporting Trials Group*. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31 (member of writing committee).
64. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. *Ugeskr Læger* 1995;157:597-8.
65. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
66. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. *Ugeskr Læger* 1995;157:5075-81.
67. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. *Health Telematics for Clinical Guidelines and Protocols*. Amsterdam: IOS Press, 1995:17-25.
68. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. *J Exp Med* 1995;182:789-99.
69. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. *Ugeskr Læger* 1995;157:6247.

70. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. *Dan Med Bull* 1996;43:96-8.
71. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. *Int J Technol Ass Health Care* 1996;12:238-46.
72. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Etske Råd; 1996:1-32.
73. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. *Social- og Hälsovårdsnytt i Norden* 1996;13:10-11.
74. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 1996;25:194-9.
75. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. *Controlled Clin Trials* 1996;17:285-90.
76. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. *Lægen* 1996;14:10-2.
77. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. *J AIDS* 1996;13:93-9.
78. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. *Recent advances in breast cancer. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb*, 1996:139-45.
79. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. *Farmakoepi-Nyt* 1996;nov:4-5.
80. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library, Issue 2. Oxford: Update Software; 1997. Updated quarterly.*
81. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.*
82. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.*
83. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
84. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. *Ugeskr Læger* 1997;159:27-8.
85. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. *Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency*. London: BMJ Books, 1997:231-49.
86. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. *BMJ* 1997;314:1238-44.
87. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. *Scand J Infect Dis* 1997;29:121-8.
88. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. *Bibl Læger* 1997;189:143-6.
89. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- γ and interleukin- 1β in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997;175:1507-10.
90. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i *Ugeskrift for Læger* 1948-1995. *Ugeskr Læger* 1997;159:4762-5.
91. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. *Ugeskr Læger* 1997;159:6721-4.
92. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997;13:1039-46.

93. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998. Updated quarterly.
94. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 1998. Updated quarterly.
95. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. *BMJ* 1998;316:811-8.
96. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for *Plasmodium falciparum* malaria: comparing a retrospective and a prospective study. *Trop Med Int Health* 1998; 3:83-8.
97. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. *Social- & Hälsovårdsnytt i Norden* 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
98. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. *BMJ* 1998;317:1105-10.
99. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. *BMJ* 1998;317:1243-5.
100. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
101. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. *Bibl Læger* 1998;190:369-80.
102. Gøtzsche PC. Lus i skindpelsen. *Ugeskr Læger* 1998;160:7610-1.
103. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. *Pharmacogenetics* 1998;8:473-9.
104. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. *Am J Clin Nutr* 1999;69:1117-22.
105. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. *Ugeskr Læger* 1999;161:932-4.
106. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørder M, Riis P. *Sundhedsvidenskabelig forskning*, 5. udg. København: FADL's Forlag, 1999:303-14.
107. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282:1752-9.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
109. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
110. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000;355:129-34.
111. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlig effekt. *Läkartidningen* 2000;97:286-7.
112. Gøtzsche PC, red. Introduktion til forskning. http://www.dadlnet.dk/dok/?2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
113. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
114. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;320:1058-61.
115. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? *Ann Rheum Dis* 2000;59:407-8.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
117. Gøtzsche PC. Cochranesamarbetets betydelse för evidensbaserad medicin. *Läkartidningen* 2000;97:3180-2.
118. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. *BMJ* 2000;321:585-6.

119. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
120. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
121. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
122. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000. (updated).
123. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. *Scand J Rheumatol* 2000;29:349-51.
124. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
125. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. *Ugeskr Læger* 2001;163:737-40.
126. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Ann Rheum Dis* 2001;60:349-52.
127. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? *Ugeskr Læger* 2001;163:1576.
128. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Ann Intern Med* 2001;134:663-94.
129. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med* 2001;344:1594-602.
130. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
131. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? *Ugeskr Læger* 2001;163:3769-72.
132. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. *BMJ* 2001;323:829-32.
133. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
134. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. *Adv Mind-Body Med* 2001;17:312-8.
135. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet* 2001;358:1340-2.
136. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. *Lancet* 2001 (<http://image.thelancet.com/extras/fullreport.pdf>).
137. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
138. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
139. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software (updated).
140. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
141. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
142. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).

143. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
144. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagan A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. *JAMA* 2002;287:2769-71.
145. Gøtzsche PC. Medicalisation of risk factors. *BMJ* 2002;324:890-1.
146. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rütther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. *Evaluation & The Health Profession* 2002;25:65-76.
147. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. *Ugeskr Læger* 2002;164:204-6.
148. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
149. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
150. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
151. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2003. Oxford: Update Software.
152. Gøtzsche PC. The debate on breast cancer screening with mammography is important. *J Am Coll Radiol* 2004;1:8-14.
153. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.
154. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.
155. Gøtzsche PC. On the benefits and harms of screening for breast cancer. *Int J Epidemiol* 2004;33:56-64.
156. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients: A marker of therapeutic success?-A 30-year Cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. *Pediatr Pulmonol* 2004;37:427-32.
157. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
158. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004;39:38-46.
159. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
160. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
161. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. *J Intern Med* 2004;256:91-100.
162. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. *The Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD001187.
163. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. *Ann Intern Med* 2004;141:781-8.
164. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
165. Johansen HK, Gøtzsche PC. Lægemedelindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
166. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
167. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. *Ugeskr Læger* 2005;167:1312-4.
168. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. *Ugeskr Læger* 2005;167:1491-4.

169. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. *J Fam Pract* 2005;54:334-8.
170. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049-52.
171. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
172. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:86-9.
173. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:90-4.
174. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. *Med J Aust* 2005;182:549-50.
175. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. *Am J Gastroenterol* 2005;100:2431-5.
176. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. *N Engl J Med* 2005;353:2811-2.
177. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
178. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. *Encyclopedia of statistical sciences*, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
Also published in: *Wiley Encyclopedia of Clinical Trials*, 2007. DOI: 10.1002/9780471462422.eoct062.
179. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. *The Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD004707.
180. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. *Trials* 2006;7:3.
181. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. *BMJ* 2006;332:538-41.
182. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. *JAMA* 2006;295:1171-3.
183. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *J Clin Epidemiol* 2006;59:336-8.
184. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. *JAMA* 2006;295:1645-6.
185. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with *Pseudomonas aeruginosa* in people with cystic fibrosis. *The Cochrane Database of Systematic Reviews* 2006, Issue 2. Art. No.: CD001399 (updated).
186. Gøtzsche PC. COX-2-hæmmere og andre nonsteroid antiinflammatoriske stoffer - hvad er fremtiden? *Ugeskr Læger* 2006;168:1972-3.
187. Gøtzsche PC. Paracetamol har samme effekt som nonsteroid antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. *Ugeskr Læger* 2006;168:1981-2.
188. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. *BMJ* 2006;333:231-4.
189. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. *BMC Medical Research Methodology* 2006;6:40.
190. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. *BMJ* 2006;333:782-5.
191. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD001877.
192. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD004684.
193. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. *Dan Med Bull* 2006;53:438-40.

194. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? *Lancet* 2006;368:1854-5.
195. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. *PLoS Med* 2007; 4(1):e19.
196. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007; 298(4):430-7.
197. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *J Clin Psychol* 2007; 63(4):373-7.
198. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. *BMC Med* 2007; 5:12.
199. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol* 2007; 36(4):847-57.
200. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18(6):805-35.
 Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007; 4(10):e297.
 Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med* 2007; 147(8):W163-94.
201. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370(9596):1453-7.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; 18(6):800-4.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ* 2007; 85(11):867-72.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med* 2007; 45(4):247-51.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624):806-8.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10):e296.
 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147(8):573-7.
202. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch Intern Med* 2007; 167(21):2289-95.
203. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. *Allergy* 2008 Jun;63(6):646-59.
204. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkanian process]. *Ugeskr Laeger* 2008 Apr 28;170(18):1537-8.
205. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Med Res Methodol* 2008 Apr 21;8:22.
206. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
207. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2008; (3):CD000193.

208. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2008; (4):CD001399.
209. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008 Apr;61(4):344-9.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. *Gac Sanit* 2008 Mar-Apr;22(2):144-50.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Rev Esp Salud Publica* 2008; 82(3):251-9.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. *Internist (Berl)* 2008; 49(6):688-93.
210. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of over-detection due to mammography screening. *Lancet Oncol* 2008 Mar;9(3):199-201.
211. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. *Månedsskr Prakt Lægegern* 2008;86 (maj):551-7.
212. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. *BMC Med Res Methodol* 2008; 8:60.
213. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. *Bioethics, Politics and Business*. Copenhagen: Nordic Council of Ministers, TemaNord 2008:119-26. ISBN 978-92-893-1728-3.
214. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. *BMJ* 2008;337:1404-7.
215. Madsen MV, Gøtzsche PC, Hróbjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. *BMJ* 2008;338:330-3.
216. Gøtzsche PC. Readers as research detectives. *Trials* 2009;10:2.
217. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. *BMJ* 2009;338:446-8.
218. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
219. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. *Bibl Læger* 2009;201:87-91.
220. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. *Ugeskr Læger* 2009;171:1206-9.
221. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. *Ugeskr Læger* 2009;171:932-3.
222. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtykke ved mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. *Skapar vården ohälsa? Allmänmedicinske reflektioner*. Lund: Studentlitteratur AB, 2009:167-75.
- Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. *Kan sundhedsvæsenet skabe usundhed? Reflektioner fra almen praksis*. København: Månedsskrift for Praktisk Lægegerning, 2009:153-162.
223. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. *BMC Medical Research Methodology* 2009, 9:1.
224. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? *PLoS Med* 2009;6(2):e23.
225. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. *J Med Ethics* 2009;35(4):268-9.

226. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. *Gac Sanit.* 2009 Mar-Apr;23(2):158.
227. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? *Ugeskr Læger* 2009;171:1963.
228. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
229. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009 Aug 18;151(4):W65-94.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009 Jul 21;6(7):e1000100.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62(10):e1-34.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009 Jul 21;339:b2700.
230. Tendal B, Higgins JP, Juni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. *BMJ* 2009 Aug 13;339:b3128.
231. Gøtzsche PC, Lundh A. Industrisponsoreret efteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. *Ugeskr Læger* 2009;171:2228-9.
232. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol.* 2009 Sep;62(9):967-73.
233. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD001877.
234. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. *Lakartidningen.* 2009;106(44):2860-1.
235. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. *Ugeskr Læger* 2009;171:3727.
236. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. *J Negat Results Biomed* 2009 Jun 10;8:7.
237. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. *Ugeskr Læger* 2009;171:3727.
238. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.
239. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. *J R Soc Med* 2010;103:14-20.
240. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974.
241. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010;340:c1241.
242. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. *Pol Arch Med Wewn* 2010;120:89-94.
243. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Obstet Gynecol* 2010 May;115(5):1063-70.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010 Mar 24;7(3):e1000251.

- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):834-40.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010 Jun 1;152(11):726-32.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010 Mar 24;8:18.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010 Mar 24;11:32.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c332.
244. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. *BMJ* 2010 Mar 30;340:c360.
245. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c869.
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):e1-37.
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. *Zhong Xi Yi Jie He Xue Bao* 2010;8(8):701-41.
246. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
247. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *Eur J Clin Pharmacol* 2010 Apr;66(4):341-7.
248. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev* 2010;(7):CD007851.
249. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. *Dan Med Bull* 2010;57(9):A4175.
250. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. *PLoS Med* 2010;7(10):e1000354.
251. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. *Ugeskr Laeger* 2010 May 24;172(21):1585.
252. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. *BMJ* 2010 Aug 10;341:c3926.
253. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010;341:c3920.
254. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. *BMJ* 2010;341:c3653.
255. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. *CMEJ* 2011;1:e10-7.
256. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. *Ugeskr Laeger* 2011;173(11):840.
257. Gøtzsche PC. Re: Time to stop mammography screening? *CMAJ* 2011;(183):1957-8.
258. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? *Videnskab.dk* 2011; <http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening>.
259. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; <http://videnskab.dk/kultur-samfund/medicinalindustriens-forskningsfusk-og-de-kobte-laeger>.
260. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. *Videnskab dk* 2011; <http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selvmod>.
261. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. *BMJ* 2011;342:d2686.
262. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. *J R Soc Med* 2011;104(9):361-9.

263. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? *Cochrane Database Syst Rev* 2011;Suppl 1:16-9.
264. Gøtzsche PC. We need access to all data from all clinical trials. *Cochrane Database Syst Rev* 2011;12:ED000035.
265. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. *J R Soc Med* 2011;104(1):41-2.
266. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. *Dan Med Bull* 2011;58(3):A4246.
267. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
268. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260(3):621-7.
269. Lundh A, Krogsboll LT, Gøtzsche PC. Access to data in industry-sponsored trials. *Lancet* 2011;378(9808):1995-6.
270. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. *Int J Risk Saf Med* 2011;23(2):125-32.
271. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:22.
272. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
273. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. *BMJ* 2011;343:d4829.
274. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. *Lancet Oncol* 2011;12(12):1118-24.
275. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12(1):249.
276. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. *Cancer Causes Control* 2012;23(1):15-21.
277. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? *Ugeskr Læger* 2012;174:297.
278. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. www.cochrane.dk.
279. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. www.cochrane.dk.
280. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. *Circ Cardiovasc Qual Outcomes* 2012 Mar 1;5(2):236-7.
281. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. *Läkartidningen* 2012;109:690-2.
282. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. *Suomen Lääkärilehti* 2012;11:856-8.
283. Grønhøj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. *PLoS One*. 2012;7(3):e33694.
284. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10(1):28-55.
285. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addiction*. 2012;107(5):900-8.
286. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. *Fokus på Kræft og sygepleje* 2012;2:18-20.
287. Lundh A, Krogsboll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;13:146.
288. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. *PLoS One* 2012;7:e41174.
289. Gøtzsche PC. Lægers råd om medicin er ikke sunde. *Politikens kronik* 2012 Nov 29.

290. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. Berlingskes kronik 2012 Dec 16.
291. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. *BMJ* 2012;345:e8522.
292. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database of Systematic Reviews*. 2012;10:CD009009.
293. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? *BMJ (Online)*. 2012;345:e7031.
294. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. *BMJ (Online)*. 2012;345:e7191.
295. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. *BMJ* 2012;345:e8462.
296. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Annals of Internal Medicine*. 2013;158(3):200-7.
297. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS medicine*. 2013;10(4):e1001419.
298. Bindsvlev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. *B M C Medical Ethics*. 2013;14:19.
299. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ (Online)*. 2013;346:e7586.
300. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews*. 2013;6:CD001877.
301. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *JAMA* 2013 jun 19;309(23):2489-90.
302. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? *International Journal of Risk and Safety in Medicine*. 2013;25(3):155-68.
303. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. *Evidence - Based Medicine (English Edition)*. 2013 jun;18(3):83-9.
304. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. *BMJ (Online)*. 2013;346:f2231.
305. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. *Systematic Reviews*. 2013;2:31.
306. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *B J C*. 2013 okt 1;109(7):2014-9.
307. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. *Pædagogisk Psykologisk Tidsskrift* 2013;50:95-100.
308. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? *Ugeskr Læger* 2013;175:2512-3.
309. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 18. udg. København: Nyt Nordisk Forlag, 2013, kap. 73.
310. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. *Lancet*. 2014;383(9913):257-66.
311. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? *BMJ*. 2014 Jan 14;348:g171.
312. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. *BMJ*. 2014 Jun 4;348:g3555.
313. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ*. 2014 Jun 4;348:g3510.
314. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. *J R Soc Med* 2014;107:256-7.
315. Gøtzsche PC. Why I think antidepressants cause more harm than good. *Lancet Psychiatry* 2014;1:104-6.
316. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. *Cochrane Database of Systematic Reviews*. 2014;9:CD002033.

317. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. *Cochrane Database of Systematic Reviews*. 2014;9:CD000026.
318. Gøtzsche PC. "Human guinea pig" asks for animal studies. *BMJ (Online)*. 2014;349:g6714.
319. Gøtzsche PC. Our prescription drugs kill us in large numbers. *Polskie Archiwum Medycyny Wewnętrznej*. 2014;124(11):628-34.
320. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. *Cochrane Database of Systematic Reviews*. 2014;9:CD000239.
321. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. *Cochrane Database of Systematic Reviews*. 2014;9:CD000969.
322. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. *Cochrane Database of Systematic Reviews*. 2014;2:CD004707.
323. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. *PLoS One*. 2014;9(11):e111964.
324. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *International journal of surgery (London, England)*. 2014 dec;12(12):1500-24.
325. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International journal of surgery (London, England)*. 2014 dec;12(12):1495-1499.
326. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. *Journal of General Internal Medicine*. 2014 sep;29(9):1283-6.
327. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. *Diagnoser*. Aarhus: Klim; 2015.
328. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? *BMJ* 2015;350:h2435.
329. Gøtzsche PC. Mammography screening is harmful and should be abandoned. *J Royal Soc Med* 2015;108(9):341-5.
330. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162(11):777-84.
331. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2015;8:CD001399.
332. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. *Nature Reviews Clin Oncol* 2015; Dec 31.
333. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. *Cochrane Database Syst Rev* 2015;1:CD010007.
334. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
335. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. *J Royal Soc Med* 2015;108:101-7.
- 336.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. *Ugeskr Læger* 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfin og morfin. *Ugeskr Læger* 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? *Ugeskr Læger* 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. *Lancet* 1986;iii:38-9.
6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. *Ugeskr Læger* 1988;150:1899-1990.
7. Gøtzsche PC, Hørding M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1000.
8. Gøtzsche PC, Hørding M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. *Lancet* 1988;Oct 29:1024.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. *Ugeskr Læger* 1989;151:901.

11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (boganmeldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkræft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (boganmeldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995:190-1.
26. Gøtzsche PC (boganmeldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (boganmeldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.
43. Gøtzsche PC. Cochranologiens vokseværk. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.
47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. Lancet 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. JAMA 2000;283:2789.

49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). Ugeskr Læger 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. Läkartidningen 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. Ugeskr Læger 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;321:568-9.
53. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed (author's reply). Läkartidningen 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. Lancet 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekompenaseret leversygdom (svar). Ugeskr Læger 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). Ugeskr Læger 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. Läkartidningen 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). Ugeskr Læger 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? Ugeskr Læger 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter humant albumin. Ugeskr Læger 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. BMJ 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? N Engl J Med 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. BMJ 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. Ugeskr Læger 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. Läkartidningen 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. Lancet 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er uberettiget. Ugeskr Læger 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues Eur J Cancer 2001, 37, 2435-2440. Eur J Cancer 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. Lancet 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: The Cochrane Library, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. Cancer 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? Lancet 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. Läkartidningen 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. Ugeskr Læger 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. Läkartidningen 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekompenaseret levercirrose. Ugeskr Læger 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. Lancet 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. <http://bmj.com/cgi/eletters/325/7361/418#24972>, 26 Aug 2002.
80. Gøtzsche PC. How to swallow one's words with a standard deviation. <http://bmj.com/cgi/eletters/325/7366/682#26186>, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. Ugeskr Læger 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). Ugeskr Læger 2002;164:3082-3.
83. Gøtzsche PC. Invited reponse to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". J Surg Oncol 2002;81:162-3.

84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. Ugeskr Læger 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. Ugeskr Læger 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. Med J Aust 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? Ugeskr Læger 2003;165:1068-70.
88. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt. Ugeskr Læger 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). Int J Epidemiol 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. Ann Intern Med 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". Ugeskr Læger 2003;165:2586-7.
92. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt (svar). Ugeskr Læger 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". Ugeskr Læger 2003;165:3026-7.
94. Gøtzsche PC. Uærlighed i lægemiddelforskning og Cochrane Centeret (svar). Ugeskr Læger 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. Politiken 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. N Engl J Med 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. Lancet 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. Lancet 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? Politiken 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". Politiken 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. Politiken 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. Ugeskr Læger 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? J Allergy Clin Immunol 2003;112:220.
105. Gøtzsche PC. Martin Bland and Janet Peacock, Statistical questions in evidence-based medicine (book review). Stat Med 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrid's XI Festforelæsning, 2003. SØLK 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). Ugeskr Læger 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). BMJ 2004;328:769-70.
109. Gøtzsche PC. Vær forsigtig med videnskabelig uredelighed. Politiken 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. Politiken 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. Ugeskr Læger 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. Ugeskr Læger 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. Politiken 2004; 15. aug., 3. sektion, s. 9.
115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. James Lind Library (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. J Natl Cancer Inst 2004;96:1257.
117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). Ugeskr Læger 2004;166:3737-8.

118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? Ugeskr Læger 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. <http://bmj.bmjournals.com/cgi/eletters/329/7472/927>, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. Int J Epidemiol 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? <http://bmj.bmjournals.com/cgi/eletters/328/7433/189>, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. <http://bmj.bmjournals.com/cgi/eletters/330/7485/220>, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. Ugeskr Læger 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. <http://bmj.bmjournals.com/cgi/eletters/330/7484/163>, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. <http://bmj.bmjournals.com/cgi/eletters/bmj.38398.469479.8Fv1>, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? Cochrane News 2005;33:1+8. Also published in: The Cochrane Collaboration Methods Groups Newsletter 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. Ugeskr Læger 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. BMJ 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. Crit Care Med 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. Ugeskr Læger 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. BMJ 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? Ugeskr Læger 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? Ugeskr Læger 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). Lancet 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. J Clin Oncol 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. N Engl J Med 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. BMJ 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). N Engl J Med 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. <http://bmj.bmjournals.com/cgi/eletters/332/7543/691>, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. J Clin Epidemiol 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. WHO International Clinical Trials Registry Platform (ICTRP) 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. <http://bmj.bmjournals.com/cgi/eletters/333/7564/374>, 2006.
145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). Ugeskr Læger 2006;168:2263-5.
146. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur. Ugeskr Læger 2006;168:3635.
147. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur 2. Ugeskr Læger 2006;168:4331-2.
148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? Am J Hypertens 2006;19:655.

149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. Cochrane Database of Systematic Reviews 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. <http://bmj.bmjournals.com/cgi/eletters/333/7572/782>, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. <http://www.annals.org/cgi/eletters/146/7/511>, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. <http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759>, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. *Lancet* 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. *Lancet* 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. *Rheumatology (Oxford)* 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. *Lancet* 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). *Int J Nurs Stud* 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. *Ugeskr Laeger* 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. *BMJ* 2008; 336(7640):344.
161. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmj.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmj.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? *Lancet* 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. *Br J Cancer* 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. *J Clin Oncol* 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. *BMJ* 2009; http://www.bmj.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. *Ugeskr Læger* 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. *BMJ rapid responses* (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. *BMJ rapid responses* (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. *BMJ rapid responses* (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. *FACT* 2009;14:105.
173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. *Allergy* 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. *BMJ*. 2009 May 27;338:b2126.
175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. *BMJ* 2009; http://www.bmj.com/cgi/eletters/339/jul21_2/b2922.

176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. *BMJ* 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmj.com/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmj.com/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. *N Engl J Med*. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. *Lakartidningen*. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmj.com/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? *BMJ* 2010. http://www.bmj.com/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. *BMJ* 2010;341:c6152.
190. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010;303(16):1597.
191. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010;172(9):733.
192. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. *Ugeskr Laeger* 2010;172(45):3126.
193. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. *J Med Screen* 2010;17(3):158-9.
194. Gøtzsche PC. Lessons from the mammography wars. *N Engl J Med* 2010;363(26):2569.
195. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. *Radiology* 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
196. Gøtzsche PC, Lundh A. Vigtig deklarering af interessekonflikter. *Dagens Medicin* 2011;13:27.
197. Gøtzsche PC. [Control should be counteracted]. *Ugeskr Laeger* 2011;173(33):1991.
198. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. *The Cochrane Collaboration* 2011; <http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review>.
199. Gøtzsche PC. Stop medicinudgifternes himmelflugt. *Politiken* 5 marts 2011. <http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/>
200. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. *BMJ* 2011;343:d4203.
201. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. *CMAJ* 2011;183:1957-8.
202. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. *Lancet Oncol* 2011;12(3):215-6.
203. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. *BMJ* 2011;343:d7533.
204. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. <http://www.cochranefeedback.com/cf/cda/citation.do?id=10133#10133> 2011;
205. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. *N Engl J Med* 2011;364(3):284-6.

206. Krogsboll LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. *Ugeskr Laeger* 2011;173(23):1671.
207. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. *Ugeskr Laeger* 2011;173(33):1989.
208. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. *Dagens Medicin* 2011;<http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-præparaterne/>.
209. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forskningssamarbejde, der foregår mellem læger og medicinalindustrien. *Ugeskr Laeger* 2011;173(8):599-600.
210. Gøtzsche PC. Selektiv rapportering er et stort problem. *Ugeskr Laeger* 2011;173(15):1154.
211. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. *Dagens Medicin* 2011;14:29.
212. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
213. Gøtzsche PC, Jørgensen KJ. RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
214. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. *BMJ* 2011;343:d6395.
215. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. *BMJ* 2011;(343):d6397.
216. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
217. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
218. Gøtzsche PCRE: Etisk analyse på automatpilot. *Dagens Medicin* 2012;<http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/>.
219. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. *BMJ* 2012; 24 April. <http://www.bmj.com/content/343/bmj.d6843?tab=responses>.
220. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. *Radiology* 2012;262(2):729-30.
221. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? *BMJ* 2012;344:e409.
222. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. *Lancet* 2012;379(9823):1297.
223. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. *Dagens Medicin* 2012;28 Sept.
224. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. *Ugeskrift for Laeger*. 2013;175(1-2):77.
225. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ*. 2013;346:f398.
226. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *New England Journal of Medicine*. 2013;368(7):677-8.
227. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. <http://www.bmj.com/content/346/bmj.f2961?tab=responses> (21 June 2013).
228. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. <http://www.bmj.com/content/346/bmj.f2865/rr/650915> (21 June 2013)
229. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. *B M J* (Online). 2013;347:f7569.
230. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *B M J*. 2013;346:f398.
231. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. *B M J* (Online). 2013;346:f3001.
232. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *New England Journal of Medicine*. 2013;368(7):677-8.
233. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. *International Journal of Cancer*. 2013;132(7):1725-1726.

234. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. Ugeskrift for Læger. 2013;175(1):74-75.
235. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? *Int J Cancer* 2013 dec 1;133(11):2754-5.
236. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. Ugeskrift for Læger. 2013 sep 9;175(37):2138.
237. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? Ugeskrift for Læger. 2013;175(1-2):77.
238. Gøtzsche PC. Tvivlsomt om lokalt appliceret NSAID har nogen effekt. Ugeskrift for læger. 2013 feb 4;175(6):377-8.
239. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. Ugeskrift for Læger. 2013 apr 8;175(15):1056.
240. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. Ugeskrift for Læger. 2013;175(49):3048.
241. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. Ugeskrift for Læger 2013;175(13):903-4.
242. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. *Lancet*. 2013 mar 9;381(9869):799.
243. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. Ugeskrift for Læger. 2013 feb 18;175(8):532.
244. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. *B M J (Online)*. 2013;347:f5227.
245. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. *Trials* 2013;14:368.
246. Gøtzsche PC. The drug industry is similiary harmful as the tobacco industry. *BMJ* 2013;347:f5193.
247. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. *BMJ* 2013;347:f5170.
248. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" *BMJ* 2013;347:f5222.
249. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. *The Times* 2013;Aug 20:25.
250. Gøtzsche PC. Incorrect statements by Novo Nordisk. *BMJ* 2013;347:f4386.
251. Gøtzsche PC. SSRI kan føre til selvmord. *Dagens Medicin* 2013; Maj 3.
252. Gøtzsche PC. Whistleblowere skal beskyttes. *Berlingske* 2013;Aug 5:21.
253. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. *BMJ* 2013;346:f819.
254. Gøtzsche PC. Comment on risk of bias tool. www.thecochranelibrary.com/details/editorial/5655441. 10 Jan 2014.
255. Gøtzsche PC. Medicinalindustriens mange løgne. *Jyllands-Posten*, kronik, 4 Jan 2014.
256. Gøtzsche PC. Psykiatri på afveje. *Politiken*, kronik, 6 Jan 2014.
257. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30. 13 Jan 2014.
258. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. *Politiken*, kronik, 21 Jan 2014.
259. Gøtzsche PC. Brug psykofarmaka mindre og bedre. *Weekendavisen* 2014; 31 Jan.
260. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. ugeskriftet.dk, 6 Feb 2014.
261. Gøtzsche PC. Om statistik og bias. *Ugeskr Læger* 2014;176:273.
262. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotzsche-responds/ 17 Feb 2014.
263. Gøtzsche PC. Vildledende forskning og markedsføring. *Ugeskr Læger* 2014;176:373.
264. Gøtzsche PC. Fejlelteringer om psykiatri. *Berlingske* 2014;23 Feb.
265. Gøtzsche PC. Fup eller fakta om dødelig medicin. *Dagens Medicin*, 28 Feb 2014.
266. Gøtzsche PC. Screening virker ikke. *Jyllands-Posten*, 8 Mar 2014.
267. Gøtzsche PC. Screening af gravide for depression. *Månedsskr Almen Praksis* 2014;326-8.
268. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. *Information* 2014; 5 April.
269. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. *Information* 2014; 9 April.
270. Gøtzsche PC. Misvisende oplysninger om Cochrane. *Altinget* 2014; 8 April.
271. Gøtzsche PC. Lægger ikke luft til mig. *Politiken* 2014; 9 April.

272. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014; 11 April.
273. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
274. Gøtzsche PC. Nyhed om Cochrane var misvisende. <http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354>. 2014;8 Apr.
275. Gøtzsche PC. Adverse effects of statins are very common. 21 May 2014. www.bmj.com/content/348/bmj.g3306/rr/698864.
276. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014; 10 Oct.
277. Bewley S, Rose L, Gøtzsche P, Blennerhassett M, Colquhoun D, Pryke M et al. Time to halt an out of control trial with ineffective oversight. B M J (Online). 2014;349:g5601.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online). 2014;349:g4790.
279. Gøtzsche PC. Muscular adverse effects are common with statins. B M J (Online). 2014;348:g3724.
280. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. B M J (Online). 2014;348:g3680.
281. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. Royal Society of Medicine. Journal. 2014 jul 10;107(7):256-257
282. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. B M J (Online). 2014;349:g5623.
283. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR. 2014 okt 6;11(11):1098.
284. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Polskie Archiwum Medycyny Wewnętrznej. 2014 dec 23;124(12):750-6.
285. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;May 18.
286. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177(13):1301-2.
287. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
288. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Polskie Archiwum Medycyny Wewnętrznej 2015;125(1-2):106-7.
289. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
290. Gøtzsche PC. Days tomme postulatere om psykiatrien. Berlingske Tidende. 2015;Sep 12;16.
291. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;Oct 9;16:1.
292. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177(18):895-6.
293. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
294. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;Oct 9;16:1.
295. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
296. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
297. Gøtzsche PC. Re: Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
298. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
299. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;Nov 4.
300. Gøtzsche PC. Svar: Dokumentationen for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177(34):1649.
301. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177(26):1303.
302. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskrift for Læger 2015;Jun 18.
303. Gøtzsche PC. Tre psykiatriprofessorer på afveje. Politiken 2015;Sep 4.
304. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;Aug 5.
305. Gøtzsche PC. Usandheder i psykiaterformands boganmeldelse. Ugeskr Læger 2015;Oct 7.
306. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;Feb 11.

307. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. *Acta oncologica* (Stockholm, Sweden). 2015;133:54.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. *Ugeskr Læger* 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. *Ugeskr Læger* 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistent HIV. *Ugeskr Læger* 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. *Ugeskr Læger* 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. *Ugeskr Læger* 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. *Läkartidningen* 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. *Tidsskr Nor Lægeforen* 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? *Ugeskr Læger* 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. *Ugeskr Læger* 2005;167:174-8.
10. Gøtzsche PC. Forbedret rapportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. *Ugeskr Læger* 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. *Sekundærpublikation. Ugeskr Læger* 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Registre og registrering af kliniske forsøg. *Sekundærpublikation. Ugeskr Læger* 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. *Ugeskr Læger* 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? *Sekundærpublikation. Ugeskr Læger* 2006;168:1658-60.
15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? *Sekundærpublikation. Ugeskr Læger* 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89 Junior lecturer, Theory of Science, University of Copenhagen.

1990-2012 Lecturer, Theory of Science, University of Copenhagen.

1992-93 Lecturer, internal medicine, Hvidovre Hospital.

Course in research methodology, human biology, University of Copenhagen, 13 May 1993 and 2-3 Feb 1994.

When is one drug better than another? Denmark's Pharmaceutical University, 2 Sept 2003.

Meta-analyses and their role in systematic reviews. Course in advanced and specialised epidemiology for students in Public Health, Copenhagen, 20 Oct 2003.

See also Lectures below, which include many for students.

2015, 15 April Lectures on Theory of Science for pharmacy students.

Postgraduate courses

CM: course manager; more recent titles have been translated into English, for convenience.

1. Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
2. CM Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
3. A-course in research methodology. National Board of Health, 15 Nov 1988.
4. A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
5. CM Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
6. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
7. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
8. Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
9. CM Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
10. PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
11. Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
12. Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
13. CM Litterature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
14. Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
15. CM Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
16. A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
17. Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
18. A-course in clinical pharmacology. National Board of Health, 5 May 1992.
19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. CM Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.
22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. CM Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. CM PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. CM PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. CM Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.

39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. CM Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. CM Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. CM Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. CM Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. CM Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. CM Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.
56. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.
58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. CM Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. CM Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. CM Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. CM Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. CM Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.

72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. CM Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. CM Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. CM Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. CM Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. CM PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.
92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.
95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.

113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
120. PhD course. Herlev, 16 June 2011.
121. Highlights i reumatologien. Korsør, 1 Sept 2011.
122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
123. Lægemedelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rhumatologie, Paris, 21-27 June 1981.
2. Dosis-respons forhold ved rheumatoid artrit. Ribe amts lægekredsförening, 5 nov 1982.
3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.

19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämman, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.
26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.
29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektørmøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsø, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.

48. IS What is sound evidence for decision making? *Medicine* 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. *Medicine* 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicin konferencen om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.
59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.
63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk föreningens vårmöte, Umeå, 20 mar 1997.
69. IS Hvilken sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabetiske komiteer og Den Centrale Videnskabetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeforeningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemeddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.

81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbetet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.
91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämman, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.
94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Institutet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.

112. IS Fallstudie Mammographie Screening. Bern's Universitat, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. Sao Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, Kbenhavn, 30 okt 2001.
122. IS Mammografiscreening - undersgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.
123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.
124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer P Vej, Kbenhavn, 12 dec 2001.
125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, Kbenhavn, 7 feb 2002.
126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
128. IS Problemer ved vurderingen af lgemiddelundersgelseser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.
129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, Kbenhavn, 19 Apr 2002.
130. IS Lgers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lgers Ytringsfrihed, Kbenhavn, 3 juni 2002.
131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.
132. IS Forskning er ikke fuldstndig objektiv - den kan drejes og vendes, s den passer politisk. Kursus for journalister, Kbenhavn, okt 2002.
133. IS Mammascreeing: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.
134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingr, 13 Nov 2002.
135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.
136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Konfernce arrangeret af Videns- og Forskningscenter for Alternativ Behandling, rhus, 27 Nov 2002.
137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.
138. IS Dronning Ingrid's Festforelsning. Hvad er vore behandlinger vrd? benr Sygehus, 8 maj 2003.
139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. lborg Sygehus, 9 sept 2003.
140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.
141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, Kbenhavn, 25 Sept 2003.

141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.
142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.
143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.
144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.
145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.
146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.
147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.
148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikere Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.
154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Ethiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämman, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.

172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary, Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.
185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.
192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitisk debat, cancer screening. Forskningens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strassbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.

217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.
228. IS Medical data transparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnige og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.
233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradys. Disbuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykoveision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
- 245 IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
- 246 IS Myter og facts om antidepressiva. Plastikkirurgisk afd., 16 Jan 2014.
- 247 IS Lægers samarbejde med industrien, Overlægeföreningen, Hvidovre Hospital, 23 Jan 2014.
- 248 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 25 Feb 2014.
- 249 IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
- 250 IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
- 251 IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
- 252 IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
- 253 IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
- 254 IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 255 IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 256 IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
- 257 IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
- 258 Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.

- 259 IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
- 260 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
- 261 IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
- 262 IS This is not a symptom. South London Gallery, 30 Apr 2014.
- 263 IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
- 264 IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
- 265 IS Dødelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
- 266 IS Psykiatri. Sundhedspolitisk Netværk, Ingeniørforeningen, 12 May 2014.
- 267 IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
- 268 IS Interessekonflikter i lægeverdenen. Panum Institutet, 19 May 2014.
- 269 IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
- 270 IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.
- 271 IS Håndtering af kommercielle interesser. Københavns Universitet, 10 June 2014.
- 272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.
- 273 IS Psykiatri på afveje. Stemmehørernetværket, Christiansborg, 17 June 2014.
- 274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.
- 275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.
- 276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.
- 277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.
- 278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usuarios (OCU), 9 Sept 2014.
- 279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.
- 280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.
- 281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.
- 282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.
- 283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.
- 284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.
- 285 IS Kan kræft forsvinde af sig selv? Møhlholm Forsikring, Carlsberg, 23 Oct 2014.
- 286 IS Danskernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.
- 287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.
- 288 IS Dødelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.
- 289 IS Kan kræft forsvinde af sig selv? Møhlholm Forsikring, Århus, 5 Nov 2014.
- 290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.
- 291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.
- 292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.
- 293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.
- 294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.
- 295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.
- 296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.
- 297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.
- 298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.

- 299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.
- 300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.
- 301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.
- 302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.
- 303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.
- 304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.
- 305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.
- 306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.
- 307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.
- 308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.
- 309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.
- 310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.
- 311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.
- 312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.
- 313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
- 314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
- 315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
- 316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
- 317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
- 318 IS Lægemedler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.
- 319 IS Depression. Rigshospitalet, 16 Apr 2015.
- 320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
- 321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
- 322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
- 323 IS The Maudsley Debate. London, 13 May 2015.
- 324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
- 325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
- 326 IS Lægemedler. Læger fra Lolland, 29 May 2015.
- 327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
- 328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
- 329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
- 330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
- 331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
- 332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
- 333 IS Drugs. Katowice, 19 Sept 2015.
- 334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
- 335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
- 336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
- 337 IS Lægemedler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
- 338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
- 339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
- 340 IS Lægemedler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
- 341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
- 342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
- 342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
- 343 IS Lægemedler. FOF Hvalsø, 23 Nov 2015.
- 344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
- 345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.

- 346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
 347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
 348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
 349 IS Deadly medicines. Alba, 3 Dec 2015.
 350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
 351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
 352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
 353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
 354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
 355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
 356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.

Research mentorships

PhD and other degrees

- 1992 - 1994 Pia Therkildsen. Clinical research behaviour in Danmark. Main tutor. PhD not finished.
 1993 - 1994 Flemming Ørnskov. Drug treatment. Main tutor. PhD not finished (emigration).
 1996 - 2001 Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
 2001 - 2004 Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
 2000 - 2004 Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
 2001 - 2005 Bodil Als-Nielsen. Hepatic encephalopathy. PhD defended 13 May 2005 at the University of Copenhagen.
 2001 - 2005 Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
 2004 - 2013 Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.
 2008 - 2009 Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
 2007 - 2010 Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
 2007 - 2011 Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
 2007 - 2013 Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
 2008 - 2013 Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
 2010 - 2015 Lasse Teis Krogsbøll. Health checks. Main tutor.
 2011 - 2015 Jeppe Schroll. Coding of harms in randomised trials. Main tutor.
 2011 - Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor.
 2012 - Tarang Sharma. Suicidality and violence on SSRIs. Main tutor.
 2012 - Michelle Ogden. Are randomised trials ethical? Main tutor.
 2014 - Pia Danborg.

Training students in research

- 2003 Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
 2003 Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
 2003 Mette Haahr, scholar student, ref. 157 in reference list above.
 2003 Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
 2003 Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
 2004 Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
 2004 Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.

- 2005 Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
- 2006 Britta Tendal, scholar student, ref. 196 in reference list above.
- 2006 Katja Maric, scholar student, ref. 196 in reference list above.
- 2007 Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
- 2007 Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
- 2007 Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
- 2009 Marija Barbateskovic, manuscript under preparation.
- 2009 Jeppe Lerche Hansen, manuscript under revision.
- 2009 Jeppe Schroll, manuscript under revision.
- 2010 Ann-Sofia Skou Thomsen, OSVAL II, marks 12
- 2010 Frida Samuelsson, OSVAL II, marks 12
- 2010 Christian Grønhøj Larsen, OSVAL II, marks 12
- 2010 Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
- 2011 Kristine Rasmussen, special subject, marks 12
- 2011 Anine Skibsted, special subject, marks 12
- 2011 Jon Egelund Jensen, special subject, marks 10
- 2012 Julie Bindslev, special subject, marks 12
- 2012 Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
- 2014 Mikkel Marquardsen, special subject, marks 12
- 2014 Andreas Bielefeldt, special subject, marks 12
- 2014 Jakob Jensen, special subject, marks 7
- 2014 Louise Jensen
- 2014 Nana Freund, no special subject
- 2014 Asmus Mortensen, special subject, marks 10
- 2015 Asger Paludan-Müller, bachelor subject, marks 12
- 2015 Kim Boesen, special subject, marks 12
- 2015 Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

- 1991 Nick Rasmussen. Randomised trial, steroids in periarthrosis.
- 1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
- 1991 Arne Gam. Meta-analysis, soft laser treatment.
- 1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
- 1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
- 1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
- 1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
- 1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
- 1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
- 1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
- 1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
- 1993 Michael Hansen. Biochemical markers for bone formation and resorption.
- 1994 Robin Bohlen. Treatment of fibromyalgia based on psychomotoric theory.
- 1994 Helle Rask. Randomised trial, volume expansion in surgery.
- 1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
- 1996 Hanne Sørensen. Randomised trial, physiotherapy in back pain.
- 1997 Judith Kongsted. Healing in breast cancer.
- 1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
- 1998 Niels Petri. Orthodontic treatment of sleep apnoea.
- 2000 Hanne Sørensen. Training for back pain.
- 2002 Lars Højgaard-Rasmussen. Asthma and osteopathy.
- 2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
- 2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

Previously

1988 - 1990	Secretary, Danish Society for Theory in Medicine.
1990	Examiner, prize report in medicine, University of Copenhagen.
1990	Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children.
1991	Member of drug committee's quality group, Rigshospitalet.
1992	Member of Ministry of Education's group in Latvia, research evaluation.
1991 - 1998	Expert, Medical Research Council's Statistical Aid Service.
1992 - 1996	Chairman, Danish Society for Theory in Medicine.
1993 - 2005	Examiner, PhD applications, Rigshospitalet.
1993 - 2005	Member of Research Council, Rigshospitalet.
1993 - 2010	Member of Drug Committee, Rigshospitalet.
1995	Member of HS's working group on clinical databases.
1998	Examiner, PhD thesis (Rasmus Licht).
1998	Chairman and examiner, PhD thesis (Palle Valentiner-Brandt).
1998	Member of ad hoc committee, Office for Scientific Integrity.
1998 - 2005	Expert, Medical Research Council's Statistical Aid Service for East Denmark.
1999	Member of ad hoc committee, Office for Scientific Integrity.
2001	Member of ad hoc committee, Office for Scientific Integrity.
2008	Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance.
2008	Examiner of case of suspected scientific misconduct in Norway.
2011	Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark
2013	Chairman, assessment of candidates for a professorship, University of Copenhagen
2014	Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen
2015	Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen

Currently

1993 -	Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org .
2004 -	Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org .
2005 -	Member of PRISMA (Quality of reporting of meta-analyses), see http://www.prisma-statement.org/ .
2005 -	Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/ .

Editorial work

1992 - 1998	Editor, Bibliotek for Læger.
1995 - 2002	Member of Editorial Board, British Medical Journal.
1995 -	Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology.
1995 -	Member of Editorial Advisory Board, The Cochrane Collaboration.
1997 - 2014	Editor, Cochrane Methodology Review Group
1997 -	Member of Advisory Board, Clinical Evidence, BMJ Publishing.
2000 -	Editorial advisor, BioMedCentral (supports PubMedCentral, USA).
2000 - 2010	Member of Scientific Board, Ugeskrift for Læger
2004 -	Member of Editorial Board, BioMedCentral Medical Research Methodology
2004 -	Member of BMJ Knowledge Advisory Board
2007 -	Academic editor, PLoS Medicine

Performed peer reviews for:

Annals of Internal Medicine
 BioMed Central Medical Research Methodology
 BioMed Central Family Practice
 BioMed Central Infectious Diseases
 Bibliotek for Læger
 BMJ

BMJ Open
 Breast Cancer Research and Treatment
 Canadian Medical Association Journal
 Cancers
 Clinical Evidence
 Clinical Trials
 Clinical Trials and Meta-analysis
 Cochrane Airways Group
 Cochrane Anaesthesia Group
 Cochrane Gynaecological Cancer Group
 Cochrane Hepato-Biliary Group
 Cochrane Infectious Diseases Group
 Cochrane Musculoskeletal Group
 Cochrane Musculoskeletal Injuries Group
 Cochrane Oral Health Group
 Controlled Clinical Trials
 Danish Medical Bulletin
 European Journal of Neurology
 Hong Kong Government Research Council
 International Journal of Cancer
 International Journal of Epidemiology
 International Journal of Technology Assessment in Health Care
 JAMA
 Journal of Clinical Epidemiology
 Journal of Medical Ethics
 Lancet
 La revue Précrire
 Medical Journal of Australia
 Medical Research Council, UK
 Medicine, Philosophy and Health Care
 Nature Reviews Nephrology
 New England Journal of Medicine
 PLoS Medicine
 Politik
 Pharmacogenetics
 PharmacoEconomics
 Radiotherapy and Oncology
 Scandinavian Journal of Gastroenterology
 Scandinavian Journal of Medicine and Science in Sports
 Scandinavian Journal of Rheumatology
 Scandinavian Journal of Social Medicine
 Science
 Statens beredning för medicinsk utvärdering
 Statistics in Medicine
 Tobacco Control
 Ugeskrift for Læger
 Vetenskapsrådet, Sverige
 Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.

6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.
14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.

Advisory Board member at international congresses

- 2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
- 3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
- 4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
- 7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
- 8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
- 9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
- 11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
- 12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
- 5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
- 15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
- 6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
- 7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
- Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.

Expert witness in court cases

- 2014 Danish High Court, double homicide attempt on methylphenidate
- 2014 Norwegian High Court, forced treatment with olanzapine
- 2015 Norwegian High Court, Patient Damage Council, oseltamivir for influenza
- 2016 Dutch High Court, double homicide case on paroxetine

Management experience

- 1977 - 1983 Founder and head, medical department, Astra-Syntex.
- 1987 - 1995 Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
- 1993 Co-founder of the Cochrane Collaboration
- 1993 - Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
- 1993 - 1996 Member of the Steering Group, the Cochrane Collaboration.

1996 - 2001 Founder and head, Cochrane Placebo Methods Group.
2002 SHL leadership course.